PYC — PYC Therapeutics Share Price
0.000.00%
Last trade - 00:00- AU$746.57m
- AU$698.79m
- AU$22.86m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.47 | ||
| Price to Tang. Book | 14.5 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 28.25 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -85.38% | ||
| Return on Equity | -112.97% | ||
| Operating Margin | -183.67% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 2.6 | 3.18 | 16.07 | 15.89 | 22.86 | 10.84 | 21.22 | 882.22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.
Directors
- Alan Tribe CHM
- Douglas Huey CEO
- Kevin Hart CFO (57)
- Rohan Hockings OTH
- Glenn Noronha OTH
- May Orfali OTH
- Natasha Santi SEC
- Jason Haddock DRC (51)
- Michael Rosenblatt DRC
- Michael Williams NED
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 9th, 2001
- Public Since
- March 30th, 2005
- No. of Shareholders
- 3,706
- No. of Employees
- 23
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 583,259,648
- Address
- Harry Perkins Institute, 6 Verdun St, NEDLANDS, 6009
- Web
- https://pyctx.com/
- Phone
- +61 861510992
- Contact
- Rohan Hockings
- Auditors
- PricewaterhouseCoopers
Upcoming Events for PYC
PYC Therapeutics Ltd Annual Shareholders Meeting
Similar to PYC
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the PYC Therapeutics share price?
As of Today at 22:47 UTC, shares in PYC Therapeutics are trading at AU$1.28. This share price information is delayed by 15 minutes.
How has the PYC Therapeutics share price performed this year?
Shares in PYC Therapeutics last closed at AU$1.28 and the price had moved by -1% over the past 365 days. In terms of relative price strength the PYC Therapeutics share price has underperformed the ASX All Ordinaries Index by -9.54% over the past year.
What are the analyst and broker recommendations for PYC Therapeutics?
The overall consensus recommendation for PYC Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the PYC Therapeutics dividend yield?
PYC Therapeutics does not currently pay a dividend.
Does PYC Therapeutics pay a dividend?
PYC Therapeutics does not currently pay a dividend.
When does PYC Therapeutics next pay dividends?
PYC Therapeutics does not currently pay a dividend.
How do I buy PYC Therapeutics shares?
To buy shares in PYC Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of PYC Therapeutics?
As of the previous close price of AU$1.28, shares in PYC Therapeutics had a market capitalisation of AU$746.57m.
Where are PYC Therapeutics shares listed?
Here are the trading details for PYC Therapeutics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: PYC
What kind of share is PYC Therapeutics?
Based on an overall assessment of its quality, value and momentum PYC Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a PYC Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in PYC Therapeutics is AU$3.41. That is 166.56% above the last closing price of AU$1.28.
Analysts covering PYC Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.10 for the next financial year.
Find out moreWhat is the trend in the PYC Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PYC Therapeutics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -3.91%.
As of the last closing price of AU$1.28, shares in PYC Therapeutics were trading -8.13% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the PYC Therapeutics PE Ratio?
The PYC Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$1.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of PYC Therapeutics?
PYC Therapeutics' management team is headed by:
- Alan Tribe - CHM
- Douglas Huey - CEO
- Kevin Hart - CFO
- Rohan Hockings - OTH
- Glenn Noronha - OTH
- May Orfali - OTH
- Natasha Santi - SEC
- Jason Haddock - DRC
- Michael Rosenblatt - DRC
- Michael Williams - NED